吉西他滨联合顺铂序贯与同期放化疗治疗局部晚期非小细胞肺癌临床比较  

Clinical Trial of GP (GEM+DDP) Sequential Therapy versus Concurrent Chemoradiotherapy for Localized Advanced Non-small Cell Lung Cancer

作　　者：陆方阳[1] 黄贵佳[1] 赵莉莉[1] 麻发强[1] 

机构地区：[1]贵阳医学院第二附属医院肿瘤科,凯里市556000

出　　处：《中国药房》2008年第20期1572-1574,共3页China Pharmacy

摘　　要：目的：比较吉西他滨＋顺铂（GP）序贯与同期放化疗治疗局部晚期非小细胞肺癌（NSCLC）的疗效和毒副反应。方法：64例Ⅲa期和Ⅲb期NSCLC患者自愿选择分成2组。序贯组：吉西他滨1250mg·m^-2第1天、第8天；顺铂30mg·m^-2，第1-3天，与放疗序贯进行。同期组：吉西他滨1000mg·m^-2第1天、第8天；顺铂20mg·m^-2第1-3天，与放疗同步进行。结果：近期疗效、毒副反应2组无统计学意义，远期疗效2组间有统计学意义。结论：GP序贯与同期放化疗治疗局部晚期NSCLC的近期疗效、毒副反应相近，但远期疗效同期组明显好于序贯组。OBJECTIVE： To evaluate the efficacy and toxicity of the sequential chemoradiotherapy of GP （GEM ＋ DDP） versus concurrent chemoradiotherapy for localized Non - small cell lung cancer （NSCLC）. METHODS： 64 patients with stage Ⅲ a and Ⅲ b NSCLC were divided into two groups： Sequential group were treated with gemcitabine （1 250 mg · m^-2, on dl and d8）, cisplatin （30 mg· m ^-2 on d1-d3） followed radiotherapy; synchronous group were treated with gemcitabine （1 000 mg · m ^-2, on d1and d8）, cisplatin （20 mg · m^- 2 on d1-d3） plus concurrent radiotherapy. RESULTS： There was no difference in short - term efficacy and toxicity between the two groups but significant difference was noted in long - term effect. CONCLUSION ： There were no difference between GP sequential treatment and concurrent chemoradiotherapy for localized NSCLC in short - term effect and toxicity, but synchronous group was better than sequential group in long - term effect.

关 键 词：非小细胞肺癌 药物疗法 放射疗法 吉西他滨 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]